Herbal formula MaZiRenWan (Hemp Seed Pill) for constipation: A systematic review with meta-analysis |
| |
| Institution: | 1. Memorial Sloan Kettering Cancer Center, Bendheim Integrative Medicine Center, 1429 First Avenue, New York, NY, 10021, United States;2. Department of Integration of Chinese and Western Medicine, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education, Beijing), Peking University Cancer Hospital & Institute, Beijing 100142, China;3. Department of Oncology, Guang''anmen Hospital, China Academy of Chinese Medical Sciences, Beixiange 5, Xicheng District, Beijing, 100053, China;1. Department of Neurosurgery, Shenzhen Key Laboratory of Neurosurgery, the First Affiliated Hospital of Shenzhen University, Shenzhen Second People''s Hospital, 3002# Sungang Road, Futian District, Shenzhen 518035, China;2. Institute of Medicinal Plant Development, Peking Union Medical College and Chinese Academy of Medical Sciences, Beijing 100193, China;1. Lunan Pharmaceutical Group Co., Ltd., State Key Laboratory of Generic Manufacture Technology of Chinese Traditional Medicine, Linyi 276006, China;2. Lunan Hope Pharmaceutical Co., Ltd., Linyi 276006, China;3. Linyi Fourth People''s Hospital, Linyi 276005, China;1. General Surgery Department, The First Affiliated Hospital of Dalian Medical University, Dalian, China;2. Institute of Integrative Medicine of Dalian Medical University, Dalian, China;3. Department of Gynaecology and Obstetrics, The First Affiliated Hospital of Dalian Medical University, Dalian, China |
| |
| Abstract: | BackgroundThere is growing interest in using herbal supplements to treat constipation; however, little evidence exists for their use.PurposeThis study evaluates the efficacy and safety of herbal formula MaZiRenWan (Hemp Seed Pill, HSP) in patients with functional or non-functional constipation.Study DesignSystematic review and meta-analysisMethodsPubMed, CENTRAL, Embase, CNKI, and Wanfang were searched through April 20, 2020 for randomized trials of HSP versus placebo or medications for all types of constipation. The primary outcomes were complete response rate, complete spontaneous bowel movement (CSBM), patient-reported satisfactory treatment rate (prSTR), and adverse events (AEs). Clinical data were analyzed using a random-effects model, and the quality of evidence was evaluated with the GRADE system.ResultsThis review includes 1681 constipation patients from 17 moderate-to-high risk of bias trials that were conducted in east Asia. Two high-quality trials showed that HSP compared with placebo significantly increased weekly CSBM (mean difference, 0.95; 95% CI: 0.56, 1.35) and had a higher complete response rate (risk ratio RR], 1.43; 95% CI: 1.20, 1.71) in patients with functional constipation. Low-quality evidence showed significant improvement in prSTR in HSP compared with conventional medications (RR, 1.79; 95% CI: 1.42, 2.25). Additionally, HSP use did not increase AEs compared with no HSP (p = 0.99).ConclusionsThis study found that HSP was effective among Asian patients with functional constipation. Rigorous trials need to be conducted in clinical populations outside of east Asia and in those with non-functional constipation to increase the generalizability of the evidence. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
